Correlation of Parkinson Disease Severity and¹⁸F-DTBZ Positron Emission Tomography

Abstract

IMPORTANCE Currently, diagnosis of Parkinson disease is mainly based on clinical criteria characterized by motor symptoms including bradykinesia, rigidity, resting tremor, and postural instability. Reliable in vivo biomarkers to monitor disease severity and reflect the underlying dopaminergic degeneration are important for future disease-modifying therapy in Parkinson disease. OBJECTIVES To use [ 18 F]9-fluoropropyl-(+)-dihydrotetrabenazine (18 F-DTBZ; [ 18 F]AV-133) positron emission tomography (PET) to explore the characteristics of vesicular monoamine transporter type 2 imaging in patients with Parkinson disease (PD) with different severity levels as well as to investigate its capability in monitoring clinical severity. DESIGN, SETTING, AND PARTICIPANTS Regional uptakes for 18 F-DTBZ PET of different disease stages were measured. Seventeen healthy control participants and 53 patients in 3 groups of mild, moderate, and advanced stages of PD were recruited for 18 F-DTBZ PET scans from the Movement Disorders Clinic in the Chang Gung Memorial Hospital, Taiwan. MAIN OUTCOMES AND MEASURES The severity of disease in patients with PD was quantified by modified Hoehn-Yahr Scale, Unified Parkinson Disease Rating Scale total scores and subscores of posture instability and gait disturbance, tremor, akinesia, and rigidity while not taking medication. Both voxelwise-and volume of interest-based image analyses were performed. The specific uptake ratio (SUR) of each volume of interest and voxel was calculated as (target uptake − reference uptake) / reference uptake using the occipital reference region from magnetic resonance imaging-based spatially normalized 18 F-DTBZ images for each participant. Average SUR images were displayed as 2-dimensional and 3-dimensional to illustrate the image patterns in each group. The nonparametric Kruskal-Wallis test on regional SUR was used for group comparison between healthy control participants and patients with PD at different stages. Quantitative parameters were correlated with severity of disease and disease duration by Spearman correlation. Voxelwise analysis for evaluating dopaminergic neuron decline of different PD stages was performed by SPM5. RESULTS The 2-dimensional and 3-dimensional 18 F-DTBZ PET images demonstrated that the reduction of vesicular monoamine transporter type 2 availability was obviously correlated with the severity of disease in patients with PD. The mean reductions of vesicular monoamine transporter type 2 density for the caudate, putamen, and substantia nigra were 21.50%, 58.20%, and 21.10% for mild PD; 60.75%, 79.49%, and 39.87% for moderate PD; and 63.94%, 83.20%, and 44.00% for advanced PD, respectively. The SURs of bilateral striatal regions exhibited significantly exponential correlations to stage; disease duration; Unified Parkinson Disease Rating Scale motor score; posture instability and gait disturbance; and akinesia, rigidity, and tremor scores. CONCLUSIONS AND RELEVANCE In PD, 18 F-DTBZ PET is a potential imaging biomarker for measuring dopaminergic ...

Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease

“…These findings are consistent with recent in vivo and postmortem findings suggesting that the primary degeneration in PD occurs at the level of the striatal terminals, followed subsequently by cell loss in the SN (34,35). These data would suggest that at the early stage of the disease, a consistent proportion of nigral cells are still viable and could be a suitable target for therapeutic strategies aimed at preserving surviving neurons, to delay the progression of the disease.…”

Effects of anesthetics on vesicular monoamine transporter type 2 binding to 18 F-FP-(+)-DTBZ: a biodistribution study in rat brain

“…Parkinson's disease [2,3,22]. In our experiment, we firstly determined the transient equilibrium of 18 F-FP-(+)-DTBZ in rat brain with a dynamic brain distribution study.…”

“…Alterations of VMAT2 function are associated with many neurodegenerative or neuropsychic disorders. In the past decades, imaging VMAT2 with positron emission tomography (PET) and 18 F-FP-(+)-DTBZ or 11 C-(+)-DTBZ, radiolabeled ligands specific to VMAT2, has demonstrated valuable potentiality for investigating VMAT2 related disorders, such as Parkinson's disease [2][3][4][5], cocaine addiction [6][7][8] and amphetamine abuse [9,10], both in animals and in humans.…”

PET imaging in neurology

“…The caudate is less affected than the anterior putamen and the anterior putamen less than the posterior putamen. The levels of 18 F-DOPA, DAT binding, and 11 C-DTBZ uptake in the striatum correlate inversely with the clinical disease severity [47][48][49]. Fluorine-18 DTBZ PET images demonstrated that the reduction of VMAT2 availability was obviously correlated with the severity of disease in patients with PD.…”